CERo Therapeutics Holdings, Inc., a clinical-stage immunotherapy biopharma focused on acute myeloid leukemia (AML), reported its latest quarterly update in May 2026. The company continues to develop its CER-1236 candidate, benefiting from FDA Fast Track and Orphan Drug designations, while navigating Nasdaq delisting and tight liquidity conditions. Its business model relies on advancing proprietary immunotherapies through costly clinical stages supported by an IP portfolio comprising 18 patents. Key growth catalysts hinge on successful product development and regulatory approvals, but risks abound from financing dilution, minimal current revenues, and healthcare reimbursement changes.